View in EDS

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Saved in:
Bibliographic Details
Title: Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).
Authors: Pascual T; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain., Vidal M; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain., Cejalvo JM; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.; Biomedical Research Institute INCLIVA, Valencia, Spain., Vega E; Medical Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain., Sanfeliu E; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Villacampa G; SOLTI Cancer Research Group, Barcelona, Spain.; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Ganau S; Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Parreño AMJ; Radiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Zamora E; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Miranda I; Radiology Department, Chief of Breast Imaging Unit. International Breast Cancer Center (IBCC) and Centro Médico Teknon, Barcelona, Spain., Delgado A; Radiology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain., Bermejo B; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.; Biomedical Research Institute INCLIVA, Valencia, Spain.; Medicine Department, Universidad de Valencia, Valencia, Spain., Seguí E; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Brasó-Maristanty F; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., de la Cruz-Merino L; Cancer Immunotherapy, Biomedicine Institute of Seville (IBIS)/CSIC, Clinical Oncology Department, University Hospital Virgen Macarena and School of Medicine, University of Seville, Seville, Spain., Juan M; Immunology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Galván P; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Gonzàlez-Farré X; SOLTI Cancer Research Group, Barcelona, Spain.; Institut Oncològic Dr. Rosell, Hospital Universitari General de Catalunya, Sant Cugat, Spain., Chillara S; SOLTI Cancer Research Group, Barcelona, Spain., Villagrasa P; Reveal Genomics, Barcelona, Spain., Pfefferle AD; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., O'Connell CE; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Ferrero-Cafiero JM; SOLTI Cancer Research Group, Barcelona, Spain., Oliveira M; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Perou CM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Prat A; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain. alprat@clinic.cat.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.; Medicine Department, University of Barcelona, Barcelona, Spain. alprat@clinic.cat.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain. alprat@clinic.cat.; Reveal Genomics, Barcelona, Spain. alprat@clinic.cat.
Source: Nature communications [Nat Commun] 2026 Feb 16; Vol. 17 (1). Date of Electronic Publication: 2026 Feb 16.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41698899
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pascual+T%22">Pascual T</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Vidal+M%22">Vidal M</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Cejalvo+JM%22">Cejalvo JM</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.; Biomedical Research Institute INCLIVA, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Vega+E%22">Vega E</searchLink>; Medical Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Sanfeliu+E%22">Sanfeliu E</searchLink>; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Villacampa+G%22">Villacampa G</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Ganau+S%22">Ganau S</searchLink>; Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Parreño+AMJ%22">Parreño AMJ</searchLink>; Radiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Zamora+E%22">Zamora E</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Miranda+I%22">Miranda I</searchLink>; Radiology Department, Chief of Breast Imaging Unit. International Breast Cancer Center (IBCC) and Centro Médico Teknon, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Delgado+A%22">Delgado A</searchLink>; Radiology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Bermejo+B%22">Bermejo B</searchLink>; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.; Biomedical Research Institute INCLIVA, Valencia, Spain.; Medicine Department, Universidad de Valencia, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Seguí+E%22">Seguí E</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Brasó-Maristanty+F%22">Brasó-Maristanty F</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22de+la+Cruz-Merino+L%22">de la Cruz-Merino L</searchLink>; Cancer Immunotherapy, Biomedicine Institute of Seville (IBIS)/CSIC, Clinical Oncology Department, University Hospital Virgen Macarena and School of Medicine, University of Seville, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Juan+M%22">Juan M</searchLink>; Immunology Department, Hospital Clínic de Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Galván+P%22">Galván P</searchLink>; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Gonzàlez-Farré+X%22">Gonzàlez-Farré X</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Institut Oncològic Dr. Rosell, Hospital Universitari General de Catalunya, Sant Cugat, Spain.<br /><searchLink fieldCode="AU" term="%22Chillara+S%22">Chillara S</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Villagrasa+P%22">Villagrasa P</searchLink>; Reveal Genomics, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Pfefferle+AD%22">Pfefferle AD</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22O'Connell+CE%22">O'Connell CE</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Ferrero-Cafiero+JM%22">Ferrero-Cafiero JM</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Oliveira+M%22">Oliveira M</searchLink>; SOLTI Cancer Research Group, Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Perou+CM%22">Perou CM</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Prat+A%22">Prat A</searchLink>; Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain. alprat@clinic.cat.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.; Medicine Department, University of Barcelona, Barcelona, Spain. alprat@clinic.cat.; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain. alprat@clinic.cat.; Reveal Genomics, Barcelona, Spain. alprat@clinic.cat.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2026 Feb 16; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 Feb 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41698899
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-026-69222-5
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pascual T
      – PersonEntity:
          Name:
            NameFull: Vidal M
      – PersonEntity:
          Name:
            NameFull: Cejalvo JM
      – PersonEntity:
          Name:
            NameFull: Vega E
      – PersonEntity:
          Name:
            NameFull: Sanfeliu E
      – PersonEntity:
          Name:
            NameFull: Villacampa G
      – PersonEntity:
          Name:
            NameFull: Ganau S
      – PersonEntity:
          Name:
            NameFull: Parreño AMJ
      – PersonEntity:
          Name:
            NameFull: Zamora E
      – PersonEntity:
          Name:
            NameFull: Miranda I
      – PersonEntity:
          Name:
            NameFull: Delgado A
      – PersonEntity:
          Name:
            NameFull: Bermejo B
      – PersonEntity:
          Name:
            NameFull: Seguí E
      – PersonEntity:
          Name:
            NameFull: Brasó-Maristanty F
      – PersonEntity:
          Name:
            NameFull: de la Cruz-Merino L
      – PersonEntity:
          Name:
            NameFull: Juan M
      – PersonEntity:
          Name:
            NameFull: Galván P
      – PersonEntity:
          Name:
            NameFull: Gonzàlez-Farré X
      – PersonEntity:
          Name:
            NameFull: Chillara S
      – PersonEntity:
          Name:
            NameFull: Villagrasa P
      – PersonEntity:
          Name:
            NameFull: Pfefferle AD
      – PersonEntity:
          Name:
            NameFull: O'Connell CE
      – PersonEntity:
          Name:
            NameFull: Ferrero-Cafiero JM
      – PersonEntity:
          Name:
            NameFull: Oliveira M
      – PersonEntity:
          Name:
            NameFull: Perou CM
      – PersonEntity:
          Name:
            NameFull: Prat A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 02
              Text: 2026 Feb 16
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1